Conduit Pharmaceuticals Inc
CDT1.590USD
+0.010+0.63%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.03MMarket Cap
LossP/E TTM
More Details of Conduit Pharmaceuticals Inc Company
CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.
Conduit Pharmaceuticals Inc Info
Ticker SymbolCDT
Company nameCDT Equity Inc
IPO dateFeb 03, 2022
CEORegan (Andrew)
Number of employees6
Security typeOrdinary Share
Fiscal year-endFeb 03
Address4851 Tamiami Trail North
CityNAPLES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code34103
Phone16464919132
Websitehttps://www.cdtequity.com/
Ticker SymbolCDT
IPO dateFeb 03, 2022
CEORegan (Andrew)
Company Executives of Conduit Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
60.09K
+68965.52%
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
4.67K
+1478.04%
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Independent Director
Independent Director
4.64K
+1676.25%
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
60.09K
+68965.52%
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
4.67K
+1478.04%
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Independent Director
Independent Director
4.64K
+1676.25%
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Corvus Capital, Ltd.
15.14%
Regan (Andrew J.)
8.59%
Bligh (James)
3.69%
Sarborg Ltd.
0.95%
Apollon Wealth Management, LLC
0.82%
Other
70.81%
Shareholders
Shareholders
Proportion
Corvus Capital, Ltd.
15.14%
Regan (Andrew J.)
8.59%
Bligh (James)
3.69%
Sarborg Ltd.
0.95%
Apollon Wealth Management, LLC
0.82%
Other
70.81%
Shareholder Types
Shareholders
Proportion
Corporation
16.13%
Individual Investor
13.24%
Investment Advisor
0.94%
Hedge Fund
0.29%
Other
69.40%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
81
20.07K
0.37%
--
2025Q3
83
20.07K
3.92%
+17.50K
2025Q2
96
2.58K
11.54%
-10.55K
2025Q1
96
13.01K
1.15%
+12.09K
2024Q4
115
728.00
11.67%
+390.00
2024Q3
109
338.00
13.69%
+91.00
2024Q2
94
246.00
16.08%
+107.00
2024Q1
73
139.00
15.73%
-829.00
2023Q4
64
117.00
14.00%
+98.00
2023Q3
54
19.00
14.28%
-108.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Corvus Capital, Ltd.
174.95K
5.71%
+154.80K
+768.19%
Jul 21, 2025
Regan (Andrew J.)
1.12M
36.58%
+1.12M
+2545454.55%
Sep 19, 2025
Bligh (James)
480.69K
15.7%
+480.00K
+69364.16%
Sep 19, 2025
Sarborg Ltd.
123.59K
4.04%
-1.00
-0.00%
Jul 08, 2025
Lewis-Hall (Freda C)
40.17K
1.31%
+35.00K
+677.51%
Aug 12, 2025
Farley (Chele Chiavacci)
37.37K
1.22%
+35.00K
+1477.42%
Aug 12, 2025
Fry (Simon Jeremy)
37.09K
1.21%
+35.00K
+1674.64%
Aug 12, 2025
UBS Financial Services, Inc.
8.47K
0.28%
+3.16K
+59.47%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 09, 2025
Merger
8→1
May 16, 2025
Merger
15→1
Jan 23, 2025
Merger
100→1
Jan 23, 2025
Merger
100→1
Jan 23, 2025
Merger
100→1
Jan 23, 2025
Merger
100→1
Date
Type
Ratio
Oct 09, 2025
Merger
8→1
May 16, 2025
Merger
15→1
Jan 23, 2025
Merger
100→1
Jan 23, 2025
Merger
100→1
Jan 23, 2025
Merger
100→1
Jan 23, 2025
Merger
100→1
FAQs
Who are the top five shareholders of Conduit Pharmaceuticals Inc?
The top five shareholders of Conduit Pharmaceuticals Inc are:
Corvus Capital, Ltd. holds 174.95K shares, accounting for 5.71% of the total shares.
Regan (Andrew J.) holds 1.12M shares, accounting for 36.58% of the total shares.
Bligh (James) holds 480.69K shares, accounting for 15.70% of the total shares.
Sarborg Ltd. holds 123.59K shares, accounting for 4.04% of the total shares.
Lewis-Hall (Freda C) holds 40.17K shares, accounting for 1.31% of the total shares.
Corvus Capital, Ltd. holds 174.95K shares, accounting for 5.71% of the total shares.
Regan (Andrew J.) holds 1.12M shares, accounting for 36.58% of the total shares.
Bligh (James) holds 480.69K shares, accounting for 15.70% of the total shares.
Sarborg Ltd. holds 123.59K shares, accounting for 4.04% of the total shares.
Lewis-Hall (Freda C) holds 40.17K shares, accounting for 1.31% of the total shares.
What are the top three shareholder types of Conduit Pharmaceuticals Inc?
The top three shareholder types of Conduit Pharmaceuticals Inc are:
Corvus Capital, Ltd.
Regan (Andrew J.)
Bligh (James)
Corvus Capital, Ltd.
Regan (Andrew J.)
Bligh (James)
How many institutions hold shares of Conduit Pharmaceuticals Inc (CDT)?
As of 2025Q4, 81 institutions hold shares of Conduit Pharmaceuticals Inc, with a combined market value of approximately 20.07K, accounting for 0.37% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.55%.
What is the biggest source of revenue for Conduit Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Conduit Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
